See more : China Petroleum & Chemical Corporation (0386.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Johnson & Johnson (JNJ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Johnson & Johnson, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Nikki Global Finance Limited (NIKKIGL.BO) Income Statement Analysis – Financial Results
- Gama Explorations Inc. (GAMA.CN) Income Statement Analysis – Financial Results
- Apollo Future Mobility Group Limited (0860.HK) Income Statement Analysis – Financial Results
- Dover Motorsports, Inc. (DVD) Income Statement Analysis – Financial Results
- The Hartford Financial Services Group, Inc. (HIG) Income Statement Analysis – Financial Results
Johnson & Johnson (JNJ)
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.16B | 79.99B | 78.74B | 82.58B | 82.06B | 81.58B | 76.45B | 71.89B | 70.07B | 74.33B | 71.31B | 67.22B | 65.03B | 61.59B | 61.90B | 63.75B | 61.10B | 53.32B | 50.51B | 47.35B | 41.86B | 36.30B | 33.00B | 29.14B | 27.47B | 23.66B | 22.63B | 21.62B | 18.84B | 15.73B | 14.14B | 13.75B | 12.45B | 11.23B | 9.76B | 9.00B | 8.01B | 7.00B | 6.42B |
| Cost of Revenue | 26.55B | 24.60B | 23.40B | 28.43B | 27.56B | 27.09B | 25.35B | 21.69B | 21.54B | 22.75B | 22.34B | 21.66B | 20.36B | 18.79B | 18.45B | 18.51B | 17.75B | 15.06B | 13.95B | 13.42B | 12.18B | 10.45B | 9.54B | 7.35B | 7.00B | 6.19B | 6.09B | 6.01B | 5.38B | 4.58B | 4.17B | 4.12B | 3.71B | 3.46B | 3.07B | 2.90B | 2.60B | 2.35B | 2.34B |
| Gross Profit | 58.61B | 55.39B | 55.34B | 54.16B | 54.50B | 54.49B | 51.10B | 50.21B | 48.54B | 51.59B | 48.97B | 45.57B | 44.67B | 42.80B | 43.45B | 45.24B | 43.34B | 38.27B | 36.56B | 33.93B | 29.69B | 25.85B | 23.47B | 21.79B | 20.47B | 17.47B | 16.54B | 15.61B | 13.46B | 11.16B | 9.96B | 9.64B | 8.74B | 7.77B | 6.69B | 6.10B | 5.41B | 4.65B | 4.08B |
| Gross Profit Ratio | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% | 66.84% | 69.84% | 69.27% | 69.40% | 68.67% | 67.78% | 68.69% | 69.49% | 70.20% | 70.96% | 70.95% | 71.76% | 72.38% | 71.65% | 70.91% | 71.22% | 71.11% | 74.79% | 74.53% | 73.83% | 73.11% | 72.21% | 71.46% | 70.92% | 70.48% | 70.06% | 70.19% | 69.17% | 68.58% | 67.77% | 67.52% | 66.37% | 63.50% |
| Research & Development | 15.05B | 14.14B | 14.28B | 12.34B | 11.36B | 10.78B | 10.55B | 9.10B | 9.05B | 8.49B | 8.18B | 7.67B | 7.55B | 6.84B | 7.17B | 7.76B | 7.68B | 7.13B | 6.31B | 5.20B | 4.68B | 3.96B | 3.59B | 2.93B | 2.60B | 2.27B | 2.14B | 0.00 | 0.00 | 1.28B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 20.11B | 19.05B | 20.12B | 22.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.11B | 19.05B | 20.12B | 22.08B | 22.18B | 22.54B | 21.42B | 19.95B | 21.20B | 21.95B | 21.83B | 20.87B | 20.97B | 19.42B | 19.80B | 21.49B | 20.45B | 17.43B | 16.88B | 15.86B | 14.13B | 12.22B | 11.99B | 10.88B | 10.50B | 8.91B | 8.72B | 10.30B | 9.10B | 6.35B | 6.95B | 6.80B | 6.08B | 5.30B | 4.62B | 4.30B | 3.85B | 3.39B | 2.99B |
| Other Expenses | 0.00 | 500.00M | -526.00M | -2.90B | -2.53B | -1.41B | -183.00M | -484.00M | 2.06B | 70.00M | -2.50B | -1.63B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 35.56B | 33.18B | 34.40B | 34.42B | 33.53B | 33.32B | 31.97B | 29.04B | 30.25B | 30.45B | 30.01B | 28.53B | 28.52B | 26.27B | 26.97B | 29.25B | 28.13B | 24.56B | 23.19B | 21.06B | 18.82B | 16.17B | 15.58B | 15.32B | 14.55B | 12.42B | 11.92B | 11.31B | 9.95B | 8.35B | 7.57B | 7.36B | 6.57B | 5.78B | 5.03B | 4.70B | 4.20B | 3.66B | 3.24B |
| Cost & Expenses | 61.81B | 57.78B | 57.80B | 62.85B | 61.09B | 60.41B | 57.33B | 50.73B | 51.79B | 53.19B | 52.36B | 50.19B | 48.88B | 45.06B | 45.42B | 47.76B | 45.88B | 39.62B | 37.14B | 34.49B | 30.99B | 26.62B | 25.12B | 22.66B | 21.55B | 18.61B | 18.01B | 17.32B | 15.33B | 12.93B | 11.74B | 11.48B | 10.28B | 9.24B | 8.10B | 7.60B | 6.80B | 6.02B | 5.58B |
| Interest Income | 1.26B | 490.00M | 53.00M | 111.00M | 357.00M | 611.00M | 385.00M | 368.00M | 128.00M | 67.00M | 74.00M | 64.00M | 91.00M | 107.00M | 90.00M | 361.00M | 452.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 772.00M | 276.00M | 183.00M | 201.00M | 318.00M | 1.01B | 934.00M | 726.00M | 552.00M | 533.00M | 482.00M | 532.00M | 571.00M | 348.00M | 451.00M | 435.00M | 296.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.49B | 6.97B | 7.39B | 7.23B | 7.01B | 6.93B | 5.64B | 3.75B | 3.75B | 3.90B | 4.10B | 3.67B | 3.16B | 2.94B | 2.77B | 2.83B | 2.78B | 2.18B | 2.09B | 2.12B | 1.87B | 1.66B | 1.61B | 1.52B | 1.44B | 1.25B | 1.07B | 1.01B | 857.00M | 724.00M | 617.00M | 560.00M | 493.00M | 474.00M | 414.00M | 391.00M | 356.00M | 275.20M | 250.50M |
| EBITDA | 23.73B | 27.17B | 30.93B | 27.50B | 28.27B | 28.10B | 24.54B | 24.92B | 22.12B | 25.03B | 23.16B | 17.96B | 16.05B | 20.35B | 18.96B | 20.20B | 16.36B | 15.77B | 15.61B | 15.02B | 13.27B | 11.82B | 9.78B | 8.08B | 7.59B | 6.96B | 5.62B | 5.46B | 4.42B | 3.58B | 2.93B | 2.78B | 2.65B | 2.63B | 2.08B | 1.70B | 1.47B | 1.79B | 985.40M |
| EBITDA Ratio | 27.86% | 37.71% | 35.38% | 29.27% | 26.96% | 27.64% | 25.95% | 30.16% | 27.15% | 28.68% | 27.40% | 27.07% | 29.93% | 26.84% | 27.51% | 27.84% | 32.86% | 29.58% | 30.91% | 31.72% | 31.71% | 32.57% | 29.63% | 27.73% | 27.64% | 29.41% | 24.81% | 25.24% | 23.45% | 22.72% | 20.73% | 20.24% | 21.32% | 23.45% | 21.33% | 18.88% | 18.29% | 25.50% | 15.35% |
| Operating Income | 23.41B | 23.19B | 20.47B | 16.95B | 15.12B | 15.62B | 14.20B | 17.93B | 15.28B | 17.42B | 15.43B | 14.53B | 16.31B | 13.59B | 14.26B | 14.92B | 17.30B | 13.60B | 13.52B | 12.90B | 11.40B | 10.16B | 8.18B | 6.57B | 6.15B | 5.71B | 4.55B | 4.45B | 3.56B | 2.85B | 2.31B | 2.22B | 2.16B | 2.16B | 1.67B | 1.31B | 1.11B | 1.51B | 734.90M |
| Operating Income Ratio | 27.49% | 28.99% | 26.00% | 20.52% | 18.42% | 19.15% | 18.57% | 24.94% | 21.80% | 23.44% | 21.64% | 21.61% | 25.08% | 22.06% | 23.03% | 23.40% | 28.31% | 25.50% | 26.76% | 27.24% | 27.24% | 27.99% | 24.77% | 22.53% | 22.38% | 24.14% | 20.10% | 20.57% | 18.90% | 18.12% | 16.37% | 16.16% | 17.36% | 19.23% | 17.09% | 14.53% | 13.84% | 21.57% | 11.44% |
| Total Other Income/Expenses | -8.35B | -2.85B | -1.77B | -3.24B | 2.21B | 2.38B | -1.22B | -1.09B | 907.00M | -574.00M | 38.00M | -3.26B | -3.79B | 420.00M | -908.00M | 760.00M | -1.93B | 990.00M | 137.00M | 482.00M | -563.00M | -387.00M | -277.00M | 303.00M | -108.00M | -846.00M | -46.00M | -270.00M | -194.00M | -126.00M | -62.00M | -70.00M | -126.00M | -369.00M | -147.00M | -8.00M | -16.00M | -592.80M | 164.30M |
| Income Before Tax | 15.06B | 19.36B | 19.18B | 16.50B | 17.33B | 18.00B | 17.67B | 19.80B | 19.20B | 20.56B | 15.47B | 13.78B | 12.36B | 16.95B | 15.76B | 16.93B | 13.28B | 14.59B | 13.66B | 12.84B | 10.31B | 9.29B | 7.90B | 6.62B | 5.75B | 4.27B | 4.58B | 4.03B | 3.32B | 2.68B | 2.33B | 2.21B | 2.04B | 1.62B | 1.51B | 1.40B | 1.19B | 390.80M | 899.20M |
| Income Before Tax Ratio | 17.69% | 24.20% | 24.36% | 19.98% | 21.12% | 22.06% | 23.12% | 27.55% | 27.39% | 27.66% | 21.69% | 20.49% | 19.01% | 27.52% | 25.45% | 26.56% | 21.74% | 27.36% | 27.03% | 27.11% | 24.62% | 25.60% | 23.93% | 22.73% | 20.94% | 18.05% | 20.22% | 18.65% | 17.60% | 17.04% | 16.49% | 16.05% | 16.37% | 14.45% | 15.52% | 15.51% | 14.89% | 5.58% | 14.00% |
| Income Tax Expense | 1.74B | 2.99B | 1.38B | 1.78B | 2.21B | 2.70B | 16.37B | 3.26B | 3.79B | 4.24B | 1.64B | 3.26B | 2.69B | 3.61B | 3.49B | 3.98B | 2.71B | 3.53B | 3.25B | 4.33B | 3.11B | 2.69B | 2.23B | 1.82B | 1.59B | 1.21B | 1.27B | 1.15B | 914.00M | 675.00M | 545.00M | 582.00M | 577.00M | 480.00M | 432.00M | 422.00M | 360.00M | 61.30M | 285.50M |
| Net Income | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B | 15.30B | 1.30B | 16.54B | 15.41B | 16.32B | 13.83B | 10.85B | 9.67B | 13.33B | 12.27B | 12.95B | 10.58B | 11.05B | 10.41B | 8.51B | 7.20B | 6.60B | 5.67B | 4.80B | 4.17B | 3.06B | 3.30B | 2.89B | 2.40B | 2.01B | 1.79B | 1.03B | 1.46B | 1.14B | 1.08B | 974.00M | 833.00M | 329.50M | 613.70M |
| Net Income Ratio | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% | 1.70% | 23.01% | 21.99% | 21.96% | 19.40% | 16.14% | 14.87% | 21.65% | 19.82% | 20.31% | 17.31% | 20.73% | 20.61% | 17.97% | 17.19% | 18.17% | 17.17% | 16.47% | 15.17% | 12.93% | 14.60% | 13.35% | 12.75% | 12.75% | 12.64% | 7.49% | 11.74% | 10.18% | 11.09% | 10.82% | 10.40% | 4.71% | 9.56% |
| EPS | 13.88 | 6.86 | 7.93 | 5.59 | 5.74 | 5.75 | 0.48 | 6.08 | 5.57 | 5.86 | 4.90 | 3.91 | 3.54 | 4.86 | 4.45 | 4.67 | 3.67 | 3.76 | 3.38 | 2.75 | 2.42 | 2.20 | 1.87 | 1.65 | 1.43 | 1.08 | 1.24 | 1.09 | 0.93 | 0.78 | 0.69 | 0.17 | 0.55 | 0.43 | 0.41 | 0.36 | 0.31 | 0.12 | 0.21 |
| EPS Diluted | 13.73 | 6.73 | 7.81 | 5.51 | 5.63 | 5.61 | 0.47 | 5.93 | 5.48 | 5.70 | 4.81 | 3.86 | 3.49 | 4.78 | 4.40 | 4.57 | 3.63 | 3.73 | 3.35 | 2.74 | 2.29 | 2.16 | 1.84 | 1.61 | 1.39 | 1.06 | 1.21 | 1.09 | 0.93 | 0.78 | 0.68 | 0.16 | 0.54 | 0.43 | 0.40 | 0.35 | 0.31 | 0.12 | 0.21 |
| Weighted Avg Shares Out | 2.53B | 2.61B | 2.63B | 2.63B | 2.63B | 2.66B | 2.68B | 2.71B | 2.76B | 2.78B | 2.82B | 2.78B | 2.72B | 2.74B | 2.76B | 2.81B | 2.88B | 2.94B | 2.98B | 2.97B | 2.97B | 3.00B | 3.03B | 2.99B | 2.99B | 2.78B | 2.67B | 2.66B | 2.58B | 2.57B | 2.61B | 2.63B | 2.66B | 2.66B | 2.67B | 2.74B | 2.73B | 2.75B | 2.92B |
| Weighted Avg Shares Out (Dil) | 2.56B | 2.66B | 2.67B | 2.67B | 2.68B | 2.73B | 2.75B | 2.79B | 2.81B | 2.86B | 2.88B | 2.81B | 2.78B | 2.79B | 2.79B | 2.84B | 2.91B | 2.96B | 3.00B | 2.99B | 3.14B | 3.05B | 3.08B | 3.10B | 3.07B | 2.83B | 2.74B | 2.73B | 2.58B | 2.61B | 2.63B | 2.63B | 2.71B | 2.69B | 2.71B | 2.78B | 2.73B | 2.75B | 2.92B |
Johnson & Johnson (JNJ) Management presents at Stifel 2024 Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ET Company Participants Michael Bodner - Group President, Heart Recovery and Circulatory Restoration Conference Call Participants Rick Wise - Stifel Rick Wise Okay everybody, Rick Wise...
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.
Johnson & Johnson (JNJ) Guggenheim Global Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) Guggenheim Global Healthcare Conference November 12, 2024 10:30 AM ET Company Participants Biljana Naumovic - Worldwide VP, Global Commercial Strategy, Oncology Mark Wildgust - VP, Global Medical Affairs Oncology Conference Call Participants Vamil Divan -...
Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program
Eli Lilly (LLY) became the second drugmaker in recent days to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facilities.
2 Of The Cheapest, High-Quality Dividend Stocks On The Market
In today's market, sticky inflation and elevated valuations make stock picking a challenge. But some dividend stocks still stand out as strong, long-term picks. These two dividend stocks offer growth potential and inflation protection. They're built to thrive in today's...
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the...
Johnson & Johnson: Tracking Well Above The Industry
In the second half of 2024, Johnson & Johnson made significant progress in developing its oncology franchise. So, Darzalex sales were $3.02 billion in the third quarter of 2024, up 20.7% year-on-year, thanks in part to its label expansions. Moreover,...
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease
The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the Phase 2 DAHLIAS study A greater than 70 percent relative improvement in systemic disease...
Source: https://incomestatements.info
Category: Stock Reports